GLSI · Greenwich LifeSciences, Inc.

🧪 Trial & FDA Catalysts

• May 2012 · Phase 3 · Results Expected · The CSM Trial: A Multicenter Study Comparing Ventral to Dorsal Surgery for Cervical Spondy
  Registry primary completion date, not a results date
• Sep 2011 · Phase 3 · Results Expected · Neurosurgery Patient Outcomes in Treating Spinal Disorders
  Registry primary completion date, not a results date
• Sep 2009 · Phase 3 · Results Expected · Greenwich Lumbar Stenosis SLIP Study
  Registry primary completion date, not a results date
• May 2003 · Phase 1/2 · Results Expected · Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cance
  Registry primary completion date, not a results date

📊 Drug Pipeline

Also used in these trials (approved or third-party drugs, not GLSI's own candidates): Carboplatin, Cetuximab, Paclitaxel.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

GLSI holds $8.9M in cash and short-term investments (as of Jun 30, 2026) and burns about $3.3M/quarter from operations, an estimated runway of 8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 45 · Elevated

• Cash runway 8 months +30
• Going-concern doubt in the latest 10-Q +15These circumstances raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date these financial statements are issued. 10-Q, Aug 2026

Recent financing filings on SEC EDGAR:

• Jun 17, 2024 · Private placement (8-K Item 3.02) · 8-K

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when GLSI files for a raise →